SureTrader SureTrader
Home > Boards > US OTC > Biotechs >

Innovus Pharmaceuticals, Inc. (INNV)

Add INNV Price Alert      Hide Sticky   Hide Intro
Moderator: BooDog, Honeycomb777, headsortails2066, ipulator_man, ML33027, stockinvestor56
Search This Board:
Last Post: 9/24/2016 11:07:13 PM - Followers: 85 - Board type: Free - Posts Today: 0

***  ALERT ***

Waiting For FDA Approval Of Fluticare Q3/Q4 2016

Approval of Fluticare could be a BILLION DOLLARS in sales annually

REDONDO BEACH, CA--(Marketwired - Jul 12, 2016) -, a leading financial news and information portal offering free real time public company filing alerts, discusses the potential impact of the anticipated FDA ruling on Innovus Pharmaceuticals' (OTCQB: INNV) ANDA filing for FlutiCare™, the company's over-the-counter treatment for allergic rhinitis.

FlutiCare™ is designed to treat non-allergic rhinitis -- better known as "hay fever" or "stuffy nose" -- which affects roughly 50 million Americans each year. While 70% of these individuals use over-the-counter products, more than half are not satisfied with the treatment option, according to an Asthma and Allergy Foundation of America survey, which suggests there's an opportunity for a prescription-strength OTC treatment option to capture market share from category leaders.

As the #1 prescription nasal steroid with over 177 million units sold since 2007, Innovus believes that the over-the-counter version of FlutiCare™ could be worth up to $1 billion per year by addressing a much wider over-the-counter market. The FDA decision is expected in the next several weeks.


The CEO has already signed an agreement for the manufacturing of Fluticare!!

Innovus Pharma Achieves Major Milestone With Securing a Manufacturing Agreement for FlutiCare in Anticipation of the FDA Decision

SAN DIEGO, CA--(Marketwired - May 31, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced that it signed a manufacturing agreement for the supply of its FlutiCare™ 60 and 120 spray/bottles.  Innovus signed the agreement in anticipation of the FDA's decision, expected between July-September of this year, on the ANDA application for the drug.


Prior to joining Innovus Pharma,

Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI)

where he helped move the company's stock price from

19 Cents to $6.00 !!

(Uplisted from OTC to NASDAQ)


Company Profile

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

Business Summary

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The company?s pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was incorporated in 2011 and is based in San Diego, California.

Bassam Damaj, Ph.D.
President and Chief Executive Officer

Dr. Bassam Damaj was appointed to serve as our President and Chief Executive Officer in January 2013. Prior to joining Innovus Pharma, Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company, from December 2009 until November 2012. At Apricus Bio, Dr. Damaj was responsible for the approval of its lead drug Vitaros, a treatment for erectile dysfunction. Dr. Damaj also signed multimillion dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda. Before Apricus Bio, Dr. Damaj was a co-founder of Bio-Quant, Inc. and served as the Chief Executive Officer and Chief Scientific Officer and a Director of Bio-Quant's board of directors from its inception in June 2000 until its acquisition by Apricus Biosciences in December 2009. In addition, Dr. Damaj was the founder, Chairman, President and Chief Executive Officer of R&D Healthcare, and the co-founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was a Member of the Scientific Advisory Board of MicroIslet, Inc. He is the author of the Immunological Reagents and Solutions reference book, the inventor of many patents and author of numerous peer reviewed scientific publications. Dr. Damaj won a US Congressional award for the Anthrax Multiplex Diagnostic Test in 2003. Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in molecular oncology from McGill University.

Robert E. Hoffman
Executive Vice President and Chief Financial Officer

Mr. Hoffman was appointed as our Executive Vice President and Chief Financial Officer on September 6, 2016. Prior to Innovus Pharma, Mr. Hoffman was Chief Financial Officer of AnaptysBio, Inc., a clinical stage biopharmaceutical company. He was part of the founding management team of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), a biopharmaceutical company, in 1997, serving as Senior Vice President, Finance and Chief Financial Officer until 2015. He also served as Chief Financial Officer for Polaris Group, a biopharmaceutical drug company, from March 2011 to August 2011. Mr. Hoffman is a member of the board of directors of CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company, Kura Oncology, Inc. (NASDAQ:KURA), a biotechnology company, and MabVax Therapeutics Holdings, Inc. (NASDAQ:MBVX), a biopharmaceutical company. He also was a member of the Financial Accounting Standards Board’s Small Business Advisory Committee until 2015 and is a member of the steering committee of the Association of Bioscience Financial Officers. Mr. Hoffman received his B.B.A. from St. Bonaventure University, and is licensed as a C.P.A. (inactive) in the State of California.


Who are the major players at Innovus Pharma?


Share Structure

Shares Outstanding :     ~ 103 Million (as of 9/7/16)    Dr. Damaj = very large shareholder

- Current cash on-hand is enough to fund operations through Q3 of 2017.  Profitability expected at that time !
- 2017 Projected Revenue of $15M, which would be approximately 3x GREATER than 2016. 

 Company Videos

Innovus Pharma CEO Provides Shareholder Update and Conference Call

Corporate Presentation April 2016


Upcoming PDUFA and ANDA Approval Dates Could Catalyze Innovus Pharma (INNV) and Lipocine (LPCN)

Innovus Pharma (INNV): Targeting $3+ Billion Markets With 13 Commercial Products

Major 2016 Accomplishments



Where can INNV products be seen?


Existing Product Line At Innovus Pharma

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
INNV News: Current Report Filing (8-k) 09/09/2016 06:08:13 AM
INNV News: Initial Statement of Beneficial Ownership (3) 09/07/2016 04:27:11 PM
INNV News: Current Report Filing (8-k) 08/29/2016 06:06:32 AM
INNV News: Notice of Effectiveness (effect) 08/26/2016 06:02:13 AM
INNV News: Prospectus Filed Pursuant to Rule 424(b)(2) (424b2) 08/25/2016 11:24:10 AM
#3528  Sticky Note MOD: Please sticky. August 2016 Corporate Prsentation pennypincher156 09/20/16 10:21:15 PM
#2422  Sticky Note For anyone willing/wondering about how they can HELP Honeycomb777 08/13/16 11:27:51 AM
#573  Sticky Note ** CEO Bassam Damaj, Ph.D.LInkedIn Profile ** headsortails2066 07/15/16 09:33:19 AM
#435  Sticky Note Innovus Pharmaceuticals Announces Successful Top Line Results From ipulator_man 06/13/16 08:22:02 AM
#3576   And even if somehow / someway bad news Honeycomb777 09/24/16 11:07:13 PM
#3575   Nostradamus speaks. And no one cares. Lol. Batermere 09/24/16 02:54:43 PM
#3574   Going downhill, Fluticare denial on the horizons. JayQuin 09/24/16 02:13:47 PM
#3573   OK, you can spend the $69 for the ShawnP123 09/23/16 06:02:47 PM
#3572   Therefore, the amount of active ingredients is the Jelly Bean 09/23/16 05:21:35 PM
#3571   no, there was no formulation mix. Not sure ShawnP123 09/23/16 04:41:33 PM
#3570   Ahh - so formulation mix was in play. Honeycomb777 09/23/16 03:00:27 PM
#3569   Shawn - with 4 months of recalmax sales, Honeycomb777 09/23/16 02:47:46 PM
#3568   I received another email which stated the amount ShawnP123 09/23/16 01:43:30 PM
#3567   I received an email back. They claimed the ShawnP123 09/23/16 12:38:59 PM
#3566   Correction: Here is my reasoning: ShawnP123 09/23/16 11:03:38 AM
#3565   Here is my reasoning: ShawnP123 09/23/16 11:02:24 AM
#3564   Do me a favor Shawn - email IR Honeycomb777 09/23/16 10:32:21 AM
#3563   Of course you obtain more shares at lower Honeycomb777 09/23/16 10:27:58 AM
#3562   The formulation is exactly the same when looking ShawnP123 09/23/16 08:56:35 AM
#3561   Hcomb, I will buy more when a buying ShawnP123 09/23/16 08:29:44 AM
#3560   So basically what you are saying is the Honeycomb777 09/22/16 10:07:43 PM
#3559   Formulation mix is very different...please google it Honeycomb777 09/22/16 10:05:27 PM
#3558   Henderson- Here is the link. Look under Aeronauticdesigns reply ShawnP123 09/22/16 07:59:55 PM
#3557   Yes they should have. It's completely ridiculous to s_Henderson 09/22/16 05:06:27 PM
#3556   Good catch. I didn't look at the dosage. ShawnP123 09/22/16 04:43:12 PM
#3555   Old news. The company can only throw that ShawnP123 09/22/16 04:38:04 PM
#3554   Hcomb- I believe without Fluticare 45- 50 days ShawnP123 09/22/16 04:34:00 PM
#3553   Hm, I'm not convinced ;-) Here is a s_Henderson 09/22/16 03:58:38 PM
#3552   Which posting on the Yahoo board are you s_Henderson 09/22/16 03:53:02 PM
#3551   Also, the EpiPen drama puts a bad light Honeycomb777 09/22/16 02:45:42 PM
#3550   I'm just surprised there is no interim update kkpennies 09/22/16 02:45:05 PM
#3549   Shawn - would love your response...I believe that Honeycomb777 09/22/16 02:37:15 PM
#3548   Unless you are a trader/MM, range trades gain ShawnP123 09/22/16 02:26:29 PM
#3547   Fluticare has no positive impact at this time. ShawnP123 09/22/16 02:23:21 PM
#3546   i love range trades!!!! slyguy8888 09/22/16 02:16:31 PM
#3545   This is going to be a beautiful thing Honeycomb777 09/22/16 12:24:57 PM
#3544   Shawn - 5m revenue guidance for 2016... This Honeycomb777 09/22/16 11:33:58 AM
#3543   ShawnP, I appreciate your level-headed, measured, albeit cynical BirdLaw924 09/22/16 11:16:42 AM
#3542   The 0.30 is being tested almost every day.When ShawnP123 09/22/16 11:12:13 AM
#3541   Certainly not vinyl plank ! #ACT Honeycomb777 09/22/16 10:36:16 AM
#3540   Say what you will about the lack of BirdLaw924 09/22/16 10:32:41 AM
#3539   no one on the bid and a fair ShawnP123 09/22/16 09:44:46 AM
#3538   Also Hendy, Vesele promotes healthy blood flow and Honeycomb777 09/21/16 07:40:27 PM
#3537   Hendy - GREAT question...the answer to it is Honeycomb777 09/21/16 07:32:47 PM
#3536   Couple of important items folks: Honeycomb777 09/21/16 07:27:38 PM
#3535   If you take a look at the active ShawnP123 09/21/16 06:40:21 PM
#3534   Hi guys! s_Henderson 09/21/16 05:40:50 PM
#3533   @.30 for life ! mike007 09/21/16 04:35:30 PM
#3532   The Curious Case of Innovus Pharmaceuticals Inc Falcon5150 09/21/16 03:06:14 PM
#3531   Also, there should be numbers from India. ShawnP123 09/21/16 11:04:22 AM
#3530   Heavy volume for the 1st hour pennypincher156 09/21/16 10:19:42 AM
#3529   Time to spread the word about this gem. Honeycomb777 09/21/16 09:45:01 AM
#3528   MOD: Please sticky. August 2016 Corporate Prsentation pennypincher156 09/20/16 10:21:15 PM
#3527   The nice thing about going in is it ShawnP123 09/20/16 03:40:38 PM